Cargando…

Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis

Vitamin D deficiency is associated with poor mental health and dysmetabolism. Several metabolic abnormalities are associated with psychotic diseases, which can be compounded by atypical antipsychotics that induce weight gain and insulin resistance. These side-effects may be affected by vitamin D lev...

Descripción completa

Detalles Bibliográficos
Autores principales: Abolghasemi, Armita, Manca, Claudia, Iannotti, Fabio A., Shen, Melissa, Leblanc, Nadine, Lacroix, Sébastien, Martin, Cyril, Flamand, Nicolas, Di Marzo, Vincenzo, Silvestri, Cristoforo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620071/
https://www.ncbi.nlm.nih.gov/pubmed/34830242
http://dx.doi.org/10.3390/ijms222212361
_version_ 1784605136740417536
author Abolghasemi, Armita
Manca, Claudia
Iannotti, Fabio A.
Shen, Melissa
Leblanc, Nadine
Lacroix, Sébastien
Martin, Cyril
Flamand, Nicolas
Di Marzo, Vincenzo
Silvestri, Cristoforo
author_facet Abolghasemi, Armita
Manca, Claudia
Iannotti, Fabio A.
Shen, Melissa
Leblanc, Nadine
Lacroix, Sébastien
Martin, Cyril
Flamand, Nicolas
Di Marzo, Vincenzo
Silvestri, Cristoforo
author_sort Abolghasemi, Armita
collection PubMed
description Vitamin D deficiency is associated with poor mental health and dysmetabolism. Several metabolic abnormalities are associated with psychotic diseases, which can be compounded by atypical antipsychotics that induce weight gain and insulin resistance. These side-effects may be affected by vitamin D levels. The gut microbiota and endocannabinoidome (eCBome) are significant regulators of both metabolism and mental health, but their role in the development of atypical antipsychotic drug metabolic side-effects and their interaction with vitamin D status is unknown. We studied the effects of different combinations of vitamin D levels and atypical antipsychotic drug (olanzapine) exposure on whole-body metabolism and the eCBome-gut microbiota axis in female C57BL/6J mice under a high fat/high sucrose (HFHS) diet in an attempt to identify a link between the latter and the different metabolic outputs induced by the treatments. Olanzapine exerted a protective effect against diet-induced obesity and insulin resistance, largely independent of dietary vitamin D status. These changes were concomitant with olanzapine-mediated decreases in Trpv1 expression and increases in the levels of its agonists, including various N-acylethanolamines and 2-monoacylglycerols, which are consistent with the observed improvement in adiposity and metabolic status. Furthermore, while global gut bacteria community architecture was not altered by olanzapine, we identified changes in the relative abundances of various commensal bacterial families. Taken together, changes of eCBome and gut microbiota families under our experimental conditions might contribute to olanzapine and vitamin D-mediated inhibition of weight gain in mice on a HFHS diet.
format Online
Article
Text
id pubmed-8620071
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-86200712021-11-27 Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis Abolghasemi, Armita Manca, Claudia Iannotti, Fabio A. Shen, Melissa Leblanc, Nadine Lacroix, Sébastien Martin, Cyril Flamand, Nicolas Di Marzo, Vincenzo Silvestri, Cristoforo Int J Mol Sci Article Vitamin D deficiency is associated with poor mental health and dysmetabolism. Several metabolic abnormalities are associated with psychotic diseases, which can be compounded by atypical antipsychotics that induce weight gain and insulin resistance. These side-effects may be affected by vitamin D levels. The gut microbiota and endocannabinoidome (eCBome) are significant regulators of both metabolism and mental health, but their role in the development of atypical antipsychotic drug metabolic side-effects and their interaction with vitamin D status is unknown. We studied the effects of different combinations of vitamin D levels and atypical antipsychotic drug (olanzapine) exposure on whole-body metabolism and the eCBome-gut microbiota axis in female C57BL/6J mice under a high fat/high sucrose (HFHS) diet in an attempt to identify a link between the latter and the different metabolic outputs induced by the treatments. Olanzapine exerted a protective effect against diet-induced obesity and insulin resistance, largely independent of dietary vitamin D status. These changes were concomitant with olanzapine-mediated decreases in Trpv1 expression and increases in the levels of its agonists, including various N-acylethanolamines and 2-monoacylglycerols, which are consistent with the observed improvement in adiposity and metabolic status. Furthermore, while global gut bacteria community architecture was not altered by olanzapine, we identified changes in the relative abundances of various commensal bacterial families. Taken together, changes of eCBome and gut microbiota families under our experimental conditions might contribute to olanzapine and vitamin D-mediated inhibition of weight gain in mice on a HFHS diet. MDPI 2021-11-16 /pmc/articles/PMC8620071/ /pubmed/34830242 http://dx.doi.org/10.3390/ijms222212361 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Abolghasemi, Armita
Manca, Claudia
Iannotti, Fabio A.
Shen, Melissa
Leblanc, Nadine
Lacroix, Sébastien
Martin, Cyril
Flamand, Nicolas
Di Marzo, Vincenzo
Silvestri, Cristoforo
Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_full Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_fullStr Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_full_unstemmed Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_short Assessment of the Effects of Dietary Vitamin D Levels on Olanzapine-Induced Metabolic Side Effects: Focus on the Endocannabinoidome-Gut Microbiome Axis
title_sort assessment of the effects of dietary vitamin d levels on olanzapine-induced metabolic side effects: focus on the endocannabinoidome-gut microbiome axis
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8620071/
https://www.ncbi.nlm.nih.gov/pubmed/34830242
http://dx.doi.org/10.3390/ijms222212361
work_keys_str_mv AT abolghasemiarmita assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT mancaclaudia assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT iannottifabioa assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT shenmelissa assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT leblancnadine assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT lacroixsebastien assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT martincyril assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT flamandnicolas assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT dimarzovincenzo assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis
AT silvestricristoforo assessmentoftheeffectsofdietaryvitamindlevelsonolanzapineinducedmetabolicsideeffectsfocusontheendocannabinoidomegutmicrobiomeaxis